|1.||Kaaks, Rudolf: 14 articles (04/2013 - 05/2002)|
|2.||Pollak, Michael N: 13 articles (07/2015 - 03/2005)|
|3.||Rinaldi, Sabina: 12 articles (04/2013 - 05/2002)|
|4.||Riboli, Elio: 12 articles (04/2013 - 05/2002)|
|5.||Flyvbjerg, Allan: 9 articles (08/2015 - 05/2003)|
|6.||Hankinson, Susan E: 7 articles (07/2015 - 01/2005)|
|7.||Tumino, Rosario: 7 articles (04/2013 - 06/2007)|
|8.||Pollak, Michael: 7 articles (02/2013 - 07/2002)|
|9.||Holly, Jeff M P: 7 articles (01/2013 - 07/2003)|
|10.||Trichopoulos, Dimitrios: 7 articles (05/2012 - 01/2003)|
|1.||Weight Loss (Weight Reduction)
05/01/1996 - "A special emphasis was placed on determining whether IGF binding proteins (IGFBPs) of patients who have lost more than 10% of their ideal body mass are structurally different from the IGFBPs of patients with no weight loss. "
04/01/1995 - "Synthetic sponges were implanted on day 7 of vitamin C deficiency and analyzed at 6 and 10 days after surgery, when there was no weight loss or induction of insulin-like growth factor binding proteins. "
08/01/1997 - "A significant reduction of IGFBP-3 and an increase of the IGF-I/IGFBP-3 molar ratio were detected after weight loss in 40 OS. "
08/01/2013 - "Greater weight loss was positively associated with change in both IGF-I (P(trend) = 0.017) and IGF-I/IGFBP-3 ratio (P(trend) < 0.001) in the diet group, but inversely with change in IGFBP-3 in the diet + exercise group (P(trend) = 0.01). "
12/01/2011 - "Reductions in TNF-α and IL-6 are consistently seen, but of a smaller magnitude, and IGF-I and IGFBP changes after weight loss are small and inconsistent. "
11/01/2015 - "[Comparison of diagnostic performance of two tests of premature rupture of membranes (IGFBP-1/PAMG-1) in clinical practice]."
05/01/2013 - "Of particular clinical relevance, PAMG-1 outperformed IGFBP-1 in the equivocal group, which comprised patients with uncertain rupture of membranes (sensitivity, 96.0% vs. 73.9%; specificity, 98.9% vs. 77.8%; PAMG-1 vs. IGFBP-1 tests, respectively). "
07/01/2003 - "Changes in the local regulation of insulin-like growth factors I and II and insulin-like growth factor-binding proteins in osteoarthritis of the canine stifle joint secondary to cruciate ligament rupture."
08/01/2015 - "The objective of this study was to evaluate the efficacy of IGFBP-1/AFP (insulin-like growth factor-binding protein-1/alpha-fetoprotein) immunoassay (Amnioquick Duo+) in diagnosing rupture of membranes (ROM). "
06/01/1996 - "In the present study we compared: the AMNI Check for detection of insulin-like growth-factor binding protein 1 (IGFBP-1); a membrane immunoassay for detection of fetal fibronectin (fFn); pH indicator paper; and, to verify a rupture of membranes in unclear cases, amniocentesis with installation of indigo carmine. "
06/01/1992 - "The low GH-BP and high IGFBP levels in patients with anorexia nervosa shown in this study, which were normalized by an improved nutritional state, would indicate resistance to GH as well as to IGFs in this condition, in which the former is in part compensated by high GH levels while the latter is not."
07/01/1988 - "In patients with anorexia nervosa, the 35 kD IGFBP levels were inversely related to the body mass index (r = -0.65, P less than 0.02)."
07/01/1988 - "The mean level of the 35 kD IGFBP in patients with acromegaly (19 micrograms/l, N = 23) was decreased by 50% in comparison with healthy adults, whereas a 2-fold elevation of the mean levels was found in both anorexia nervosa patients (70 micrograms/l, N = 13) and adult patients with GH deficiency (69 micrograms/l, N = 22). "
06/01/1999 - "The present study suggested that ALS was regulated by nutritional status, the same as IGF-I, IGFBP-2 and IGFBP-3; but the serum IGFBP-2 was the best predictor of BMI as nutritional status marker among the parameters in patients with anorexia nervosa."
09/01/1992 - "The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins."
|4.||Metabolic Bone Diseases (Osteopenia)
07/01/1995 - "The highest dose of rhIGF-I/IGFBP-3 used in this study showed the best results in promoting cortical and cancellous bone formation, and appears to be promising therapy for human osteopenias."
07/01/1995 - "Sixteen-week-old Sprague-Dawley rats were ovariectomized (Ovx) or sham-operated and housed for 8 weeks to develop osteopenia prior to systemic administration of rhIGF-I (0.9 and 2.6 mg/kg) alone or the rhIGF-I/IGFBP-3 (0.9, 2.6 and 7.5 mg/kg) complex. "
04/01/2002 - "Our beta-thalassaemic patients, in spite of normalizing hemoglobin levels, adequate hormone replacement and chelation therapies, showed osteopenia and an unbalanced bone turnover with an increased resorptive phase and a decreased formation phase probably correlated to low levels of IGF-I and IGFBP-III observed in our study."
|5.||Body Weight (Weight, Body)
01/01/2002 - "X-ray examinations and blood analyses (including IGF-1 and IGF-binding proteins) were performed, and body weight and body temperature were taken throughout the experiment. "
05/01/1995 - "Treatment of Ovx rats with the rhIGF-I/IGFBP-3 complex increased body weight, lean body mass, and femoral BMC and BMD.(ABSTRACT TRUNCATED AT 250 WORDS)"
04/01/1995 - "All rats treated with rhIGF-I or the rhIGF-I/IGFBP-3 complex had increased body weights, corresponding to a dose-dependent increase in lean body mass. "
04/15/2012 - "IGFBP-3/-5 KO mice showed a phenotype of lower plasma IGF-I concentration, but greater body weight and relative mass of visceral organs, compared with WT mice (P < 0.001). "
11/01/2003 - "Thus, while selection for high versus low serum IGF-I concentrations has resulted in divergence between the selection lines and also in changes in body weights, it has not resulted in changes in serum IGFBP levels. "
|1.||Insulin-Like Growth Factor I (IGF-1)
|3.||Insulin-Like Growth Factor Binding Proteins
|4.||Insulin-Like Growth Factor Binding Protein 3
|5.||Insulin-Like Growth Factor II (Somatomedin A)
|6.||Insulin-Like Growth Factor Binding Protein 1
|7.||Growth Hormone (Somatotropin)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Phototherapy (Light Therapy)
|4.||Protein-Restricted Diet (Diet, Protein Restricted)
|5.||Chelation Therapy (Therapy, Chelation)